Dr. Zeidan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
20 York St
New Haven, CT 06510Phone+1 203-688-4242Fax+1 203-688-5013
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2010 - 2013
University of Jordan Faculty of MedicineClass of 2001
Rochester General HospitalResidency, Internal Medicine
Certifications & Licensure
CT State Medical License 2014 - 2025
MD State Medical License 2010 - 2015
NY State Medical License 2007 - 2014- American Board of Internal Medicine Hematology
Clinical Trials
- Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents Start of enrollment: 2017 Jun 23
- Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease Start of enrollment: 2019 Jun 26
- GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia Start of enrollment: 2019 Dec 06
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsBeyond HMAs: Novel Targets and Therapeutic Approaches.Ted M Getz, Jan P Bewersdorf, Tariq Kewan, Jessica M Stempel, Aram Bidikian
Seminars in Hematology. 2024-12-01 - Aplastic anemia in association with multiple myeloma: clinical and pathophysiological insights.Tinatin Muradashvili, Yuxin Liu, Jennifer VanOudenhove, Sean X Gu, Diane S Krause
Leukemia & Lymphoma. 2024-12-01 - Cost-effectiveness of Enasidenib versus conventional care for older patients withmutant refractory/relapsed AML.Abdulrahman Alhajahjeh, Kishan K Patel, Rory M Shallis, Nikolai A Podoltsev, Tariq Kewan
Leukemia & Lymphoma. 2024-11-19
Lectures
- A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of MBG453 Added to Hypomethylating Agents (HMAs) in Patients (pts) with Intermediate, High, or Very High...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- New Therapies for Better Patient Outcomes in Acute Myeloid Leukemia: Integration of Recent Data Sets Into Clinical Practice60th American Society of Hematology Annual Meeting - 11/30/2018
Press Mentions
Is AML Harder to Treat After Relapse?March 6th, 2020
Trovagene (TROV) Stock: Providing New Cancer Treatment Options with OnvansertibDecember 11th, 2018
Breaking News: Trovagene Reports New Data from Phase 1b/2 Study of Onvansertib Demonstrates Response to Treatment in Relapsed/Refractory AMLDecember 3rd, 2018- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
